Please login to the form below

Orion Pharma

This page shows the latest Orion Pharma news and features for those working in and with pharma, biotech and healthcare.

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga. Bayer and Orion have put some meat on the bones of their phase 3 trial of darolutamide in non-metastatic ... Orion and Bayer have another phase 3 trial on the go in patients with

Latest news

Biogen picks up another drug from wide-ranging Ionis alliance

It was joined last year by Mitsubishi Tanabe Pharma’s Radicava/Radicut (edaravone) last year, which provides another options, but there is still a desperate need for additional therapies. ... Pharma’s ODM-109 (oral levosimendan) which was advanced to
Bayer preps filings for new prostate cancer drug

Bayer, which co-develops darolutamide with Finland’s Orion Pharma under the terms of a 2014 licensing deal, says it will discuss the data from ARAMIS with regulatory authorities to see ... Under the terms of their 2014 agreement, Bayer has the right to
Alzheimer's disease pipeline takes multiple hits

Other AChE inhibitors in phase II development include methanesulfonyl fluoride (SeneXta Therapeutics), ladostigil (Avraham), rilapladib (GlaxoSmithKline) and R-phenserine (QR Pharma). ... 2013). Orion Pharma is developing an oral 2c adrenergic receptor
Nycomed and Orion in Easyhaler deal

Orion is developing a budesonide-formoterol formulation that combines budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator. ... Orion has another Easyhaler research programme in progress to develop a
2011 IPA Best of Health Awards winners

Puffalot', Easyhaler for Orion Pharma, by Langland. 'Rabbit', Easyhaler for Orion Pharma, by Langland. ... Healthcare Professional, Mixed Media Campaign. 'A Little Less Different', Easyhaler for Orion Pharma, by Langland.

More from news
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

Orion appoints VP of oncology, R&D

He said: “My new position at Orion allows me to maintain and deepen my research focus, which is to develop such treatments for cancer patients wherever they live. ... I hope that my long background in the academia will help in the initiation of new

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....